Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Ballinger and lung disease
Previous Study | Return to List | Next Study

Identification of Novel Markers of Human Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02369575
Recruitment Status : Recruiting
First Posted : February 24, 2015
Last Update Posted : January 20, 2017
Sponsor:
Information provided by (Responsible Party):
Megan Ballinger, Ohio State University

Brief Summary:
The purpose of this study is to investigate new therapies for advanced lung disease.

Condition or disease Intervention/treatment
Lung Diseases, Interstitial Other: novel biomarkers of lung disease

Detailed Description:
This research study is being conducted to learn about the progression and cause of lung disease. By agreeing to be a part of this study, you will allow the lung tissue which would normally have been discarded after your procedure, to be used for research purposes to allow us to understand more about your condition which may potentially lead to novel treatments and therapeutics. For this study, the investigators will isolate specific cells from the lung tissue and measure cellular, molecular and genetic mechanisms responsible for regulating lung disease. No other type of research will be performed on these samples nor will the samples be given to other investigators for unrelated research.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Identification of Novel Markers of Human Lung Disease
Study Start Date : February 2015
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2030

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: novel biomarkers of lung disease
    we will be identifying molecular, genetic, and cellular markers of lung disease


Primary Outcome Measures :
  1. The development of novel therapeutics for interstial lung disease [ Time Frame: 10 years ]
    Our research on these human lung cells will provide critical data which will aid in the diagnosis and treatment of a variety of different lung diseases, which have no cure.


Biospecimen Retention:   Samples With DNA
lung cells


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients on lung transplant waiting list
Criteria

Inclusion Criteria:

  • any one on lung transplant list

Exclusion Criteria:

  • HIV positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02369575


Contacts
Layout table for location contacts
Contact: Megan Ballinger 614-292-6578 megan.ballinger@osumc.edu

Locations
Layout table for location information
United States, Ohio
Davis Heart and Lung Research Institute Recruiting
Columbus, Ohio, United States, 43210
Contact: Megan Ballinger       megan.ballinger@osumc.edu   
Sponsors and Collaborators
Ohio State University
Investigators
Layout table for investigator information
Principal Investigator: Megan Ballinger Ohio State University

Layout table for additonal information
Responsible Party: Megan Ballinger, Research Asst Professor, Ohio State University
ClinicalTrials.gov Identifier: NCT02369575    
Other Study ID Numbers: 2014H0367
First Posted: February 24, 2015    Key Record Dates
Last Update Posted: January 20, 2017
Last Verified: January 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases